Literature DB >> 10665704

The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial.

A Catanzaro1, S Perry, J E Clarridge, S Dunbar, S Goodnight-White, P A LoBue, C Peter, G E Pfyffer, M F Sierra, R Weber, G Woods, G Mathews, V Jonas, K Smith, P Della-Latta.   

Abstract

CONTEXT: In laboratory trials, nucleic acid amplification tests for the diagnosis of tuberculosis (TB) are more accurate than acid-fast bacilli (AFB) smear microscopy and are faster than culture. The impact of these tests on clinical diagnosis is not known.
OBJECTIVE: To assess the performance of a nucleic acid amplification test, the enhanced Mycobacterium tuberculosis Direct (E-MTD) test, against a uniform clinical standard stratified by level of clinical suspicion.
DESIGN: Prospective multicenter trial conducted between February and December 1996, documenting the clinical suspicion of TB at enrollment and using final comprehensive diagnosis as the criterion standard.
SETTING: Six urban medical centers and 1 public health TB clinic. PATIENTS: A total of 338 patients with symptoms and signs consistent with active pulmonary TB and complete clinical diagnosis were stratified by the clinical investigators to be at low (< or =25%), intermediate (26%-75%), or high (>75%) relative risk of having TB. MAIN OUTCOME MEASURES: Sensitivity, specificity, and positive and negative predictive values of the E-MTD test in clinical suspicion of groups with low (n = 224); intermediate (n = 68); and high (n = 46) clinical suspicion of TB.
RESULTS: Based on comprehensive clinical diagnosis, sensitivity of the E-MTD test was 83%, 75%, and 87% for low, intermediate, and high clinical suspicion of TB, respectively, and corresponding specificity was 97%, 100%, and 100% (P = .25). Positive predictive value of the E-MTD test was 59% (low), 100% (intermediate), and 100% (high) compared with 36% (low), 30% (intermediate), and 94% (high) for AFB smear. Corresponding negative predictive values were 99%, 91%, and 55% [corrected] (E-MTD test) vs 96%, 71%, and 37% (AFB smear).
CONCLUSIONS: For complex diagnostic problems like TB, clinical risk assessments can provide important information regarding predictive values more likely to be experienced in clinical practice. For this series, a clinical suspicion of TB was helpful in targeting areas of the clinical spectrum in which nucleic acid amplification tests can make an important contribution.

Entities:  

Mesh:

Year:  2000        PMID: 10665704     DOI: 10.1001/jama.283.5.639

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  40 in total

Review 1.  Relevance of commercial amplification methods for direct detection of Mycobacterium tuberculosis complex in clinical samples.

Authors:  Claudio Piersimoni; Claudio Scarparo
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

2.  Comparison of the BDProbeTec ET system with the Cobas Amplicor PCR for direct detection of Mycobacterium tuberculosis in respiratory samples.

Authors:  Y Iinuma; K Senda; N Fujihara; T Saito; S Takakura; M Shimojima; T Kudo; S Ichiyama
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-16       Impact factor: 3.267

3.  Effectiveness of an integrated real-time PCR method for detection of the Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples in an area of low tuberculosis prevalence.

Authors:  Raquel Moure; Rogelio Martín; Fernando Alcaide
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

4.  Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method.

Authors:  Raquel Moure; Laura Muñoz; Miriam Torres; Miguel Santin; Rogelio Martín; Fernando Alcaide
Journal:  J Clin Microbiol       Date:  2010-12-29       Impact factor: 5.948

Review 5.  Molecular diagnostics in tuberculosis.

Authors:  V C C Cheng; W W Yew; K Y Yuen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

6.  Cost-effectiveness of different strategies for amplified Mycobacterium tuberculosis direct testing for cases of pulmonary tuberculosis.

Authors:  Renata L Guerra; Nancy M Hooper; James F Baker; Roya Alborz; Derek T Armstrong; Julia A Kiehlbauch; Marcus B Conde; Susan E Dorman
Journal:  J Clin Microbiol       Date:  2008-09-17       Impact factor: 5.948

7.  Performance assessment of two commercial amplification assays for direct detection of Mycobacterium tuberculosis complex from respiratory and extrapulmonary specimens.

Authors:  Claudio Piersimoni; Claudio Scarparo; Paola Piccoli; Alessandra Rigon; Giuliana Ruggiero; Domenico Nista; Stefano Bornigia
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

8.  Direct detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis in auramine-rhodamine-positive sputum specimens by real-time PCR.

Authors:  Maite Ruiz; Maria J Torres; Ana C Llanos; Aurelio Arroyo; Jose C Palomares; Javier Aznar
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  Tuberculosis of the breast.

Authors:  Salim Baharoon
Journal:  Ann Thorac Med       Date:  2008-07       Impact factor: 2.219

Review 10.  New diagnostic methods for tuberculosis.

Authors:  Melissa R Nyendak; Deborah A Lewinsohn; David M Lewinsohn
Journal:  Curr Opin Infect Dis       Date:  2009-04       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.